Potential of an anti-bevacizumab idiotype scFv DNA-based immunization to elicit VEGF-binding antibody response

Anti-idiotype antibodies have been considered for vaccination approaches against different diseases, including cancers. Based on that, we previously described an anti-bevacizumab idiotype monoclonal antibody, 10.D7, that revealed detectable antitumor effects on a vascular endothelial growth factor (...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva, Tábata Almeida, Aguiar, Rodrigo Barbosa, Mori, Marcelo, Machado, Gabriel Esquitini, Hamaguchi, Barbara, Machado, Marcelo Ferreira Marcondes, Moraes, Jane Zveiter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734904/
https://www.ncbi.nlm.nih.gov/pubmed/36482074
http://dx.doi.org/10.1038/s41434-022-00376-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734904/
https://www.ncbi.nlm.nih.gov/pubmed/36482074
http://dx.doi.org/10.1038/s41434-022-00376-9

Ejemplares similares